Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII by Kearney S, Raffini LJ, Pham TP, Lee XY, von Mackensen S, Landorph A, Takedani H, Oldenburg J

Get full text

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). by Curry, N, Albayrak, C, Escobar, M, Andre Holme, P, Kearney, S, Klamroth, R, Misgav, M, Négrier, C, Wheeler, A, Santagostino, E, Shima, M, Landorph, A, Tønder, SM, Lentz, SR

Efficacy and safety analyses of recombinant factor VIIa in severe post-partum hemorrhage by Caram-Deelder, C, McKinnon Edwards, H, Zdanowicz, JA, van den Akker, T, Birkegård, C, Blatný, J, van der Bom, JG, Colucci, G, van Duuren, D, van Geloven, N, Henriquez, DDCA, Knight, M, Korsholm, L, Landorph, A, Lavigne Lissalde, G, McQuilten, ZK, Surbek, D, Wellard, C, Wood, EM, Mercier, FJ